What it sells
Making hard molecules for Pharma and Biotech
Business model breakdown
Buyer: who owns the budget?
UnverifiedHeads of medicinal/process chemistry at pharma and biotech.
Trigger: what makes them buy now?
Slow multi-step synthesis route design and reaction condition optimization.
Workflow: what inputs become what output?
Selenium proposes ranked retrosynthesis routes; Palladium designs HTE plates screening catalysts, ligands, bases, solvents; Cobalt for execution.
Economics: what it saves and how it charges
Claims 70% faster route design.
Distribution: how it reaches customers
Web app (app.b12-labs.com) with Get Started and Request a Demo; SOC 2 Type 2.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2025 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.